Ad-hoc | 28 October 2002 08:36

MorphoSys AG correction

MorphoSys Announces Share Issuance for XOMA License Ad-hoc-announcement processed and transmitted by DGAP. The issuer is solely responsible for the content of this announcement. ——————————————————————————– Corrected announcement on behalf of the issuer: In the ad hoc announcement on 24 October 2002, 7.31 a.m., the first paragraph, first sentence, instead of: “MorphoSys AG (Neuer Markt: MOR), the Munich-based biotechnology company, today announced that the Management Board has resolved to issue 303,466 shares to XOMA after a capital increase against contribution in kind, subject to registration in the commercial register.” it must read: “MorphoSys AG (Neuer Markt: MOR), the Munich-based biotechnology company, today announced that the Management Board has resolved to issue 363,466 shares to XOMA after a capital increase against contribution in kind, subject to registration in the commercial register.”. In the first paragraph, last sentence, instead of: “The shares issued to XOMA represent approx. 7.7 % of the outstanding share capital of MorphoSys AG.” it must read: “The shares issued to XOMA represent approx. 9.2 % of the outstanding share capital of MorphoSys AG.”. In the second paragraph, last sentence, instead of: “The share issuance announced today represents full and complete satisfaction of the outstanding obligations under said transaction.” it must read: “Except for milestone payments and royalties the share issuance announced today, pending share registration, represents full and complete satisfaction of the outstanding obligations under said transaction.”. The complete corrected announcement is: MorphoSys Announces Share Issuance for XOMA License MorphoSys AG (Neuer Markt: MOR), the Munich-based biotechnology company, today announced that the Management Board has resolved to issue 363,466 shares to XOMA after a capital increase against contribution in kind, subject to registration in the commercial register. As a contribution, XOMA granted a license to MorphoSys as part of a transaction announced earlier this year. The share capital was raised under exclusion from preemptive rights under the Company’s articles of association. The shares issued to XOMA represent approx. 9.2 % of the outstanding share capital of MorphoSys AG. In February 2002, MorphoSys and XOMA signed a cross-license agreement for their antibody-related technologies. MorphoSys and its partners received a license from XOMA to use XOMA’s antibody expression technology for the development and production of antibody products using MorphoSys’ phage display-based HuCAL antibody library. XOMA receives a license to use the MorphoSys HuCAL GOLD library and, among other financial terms, a one-time license payment from MorphoSys. Except for milestone payments and royalties the share issuance announced today, pending share registration, represents full and complete satisfaction of the outstanding obligations under said transaction. end of ad-hoc-announcement (c)DGAP 28.10.2002 ——————————————————————————– WKN: 663200; ISIN: DE0006632003; Index: Nemax 50 Listed: Neuer Markt in Frankfurt; Freiverkehr in Berlin, Bremen, Düsseldorf, Hamburg, Hannover, München und Stuttgart 280836 Okt 02